Facebook
Twitter
LinkedIn
ForwardBetting on BTK Inhibitors in CLL: Where are We Now and Where are We Going?
This initiative is targeted to addressing the professional practice of pharmacists in hospitals, health systems, ambulatory care clinics, and other settings. Attendees of this activity will gain insight into the latest clinical and scientific advances in the treatment and management of patients with chronic lymphocytic leukemia (CLL) using BTK inhibitors (BTKis), including the latest approvals, the most current safety and efficacy data, and expert insights into addressing challenges of CLL treatment using BTKis. Using a case-based approach, discussion on anticipating and managing adverse events, therapy selection, and improving adherence will be incorporated into this activity.
Presented by Creative Educational Concepts, Inc. and supported by independent educational grants from AstraZeneca
Learning Objectives
- Describe the role of the BCR (B-cell receptor) pathway in malignant B-cell survival.
- Explore the therapeutic rationale for targeting the BCR pathway in CLL and other B-cell malignancies.
- Assess the latest safety and efficacy data for BTKis (BTK inhibitors) in TN (treatment-naïve) and R/R (relapsed/refractory) CLL and examine strategies to overcome resistance seen in these agents.
- Using a case-based approach, appraise effective strategies to integrate BTK inhibitors into the CLL treatment paradigm, recognize and appropriately manage adverse events, and answer challenging clinical issues pharmacists may encounter in their practice.
Emily K. Dotson, PharmD, BCOP
Clinical Pharmacist Specialist–Hematology Lead
Hematology Inpatient/Outpatient
The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
The Ohio State University
Columbus, Ohio
PLANNER AND FACULTY DISCLOSURES
In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.
Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as an entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.
Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.
PLANNERS
Vanessa Carranza, PharmD, has no relevant financial relationships to disclose in relation to the content of this activity.
PRESENTERS
Emily K. Dotson, PharmD, BCOP–has disclosed that she is a consultant for AstraZeneca.
PEER REVIEWER
Benyam Muluneh, PharmD, BCOP, CPP–has no relevant financial relationships to disclose in relation to the content of this activity.
In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Pharmacy (ACPE)
This application-based activity is approved for 1.0 contact hours (.10 CEUs) of continuing pharmacy education credit JA0007101-0000-20-018-H01-P.
Upon completion of a CE request form, pharmacy credit will be reported directly to the National Association of Boards of Pharmacy® (NABP®) CPE Monitor electronic CE tracking system.
Available Credit
- 1.00 ACPE Pharmacy
- 1.00 Participation